How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Donation Market
- By Donation Type: Whole Blood Donation, Platelet Donation (Apheresis), Plasma Donation (Plasmapheresis), Double Red Cell Donation
- By Donor Type: Voluntary Donors, Replacement Donors, Paid Donors
- By End User: Hospitals and Clinics, Blood Banks, Research and Diagnostic Laboratories
- By Collection Site: Fixed Donation Centers, Mobile Blood Donation Camps, Hospital-Based Collection Units
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Whole Blood Donation leads By Donation Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 265 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.159 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.167 →
Full report · locked preview
Everything inside the Blood Donation Market report
A complete, evidence-based study - 11 chapters and 111 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Donation Type 4
Donor Type 3
End User 3
Collection Site 3
Companies profiled
Fresenius Kabi
Terumo Corporation
Grifols
Haemonetics Corporation
Macopharma
Sartorius AG
Baxter International Inc.
Octapharma AG
Kamada Ltd.
B. Braun Melsungen AG
MacoPharma
LFB Group
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Grifols
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Haemonetics Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Macopharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Baxter International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Octapharma AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Kamada Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MacoPharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →LFB Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →CSL Behring
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sanquin Blood Supply Foundation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →NHS Blood and Transplant
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$8,605M by 2033 · 9.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Whole Blood Donation39.2
- Platelet Donation (Apheresis)22.7
- Plasma Donation (Plasmapheresis)21.8
- Double Red Cell Donation16.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,352M → $2,845M · 9.7%
Europe$942.1M → $1,826M · 8.6%
Asia Pacific$860.2M → $1,889M · 10.3%
Latin America$532.5M → $1,100M · 9.5%
Middle East and Africa$409.6M → $877.1M · 10.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.672026
9.682027
9.702028
9.712029
9.732030
9.732031
9.742032
9.752033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius Kabi16.0
- Terumo Corporation14.3
- Grifols9.6
- Haemonetics Corporation7.4
- Macopharma6.8
- Sartorius AG17.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Donation Type30.5%
Donor Type24.1%
End User24.9%
Collection Site20.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe21.4
- Asia Pacific22.1
- Latin America12.9
- Middle East and Africa10.3
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius Kabi | 88 | 90 | 94 | 86 | 83 | 85 | 88 |
| Terumo Corporation | 81 | 80 | 88 | 69 | 83 | 79 | 80 |
| Grifols | 80 | 73 | 75 | 84 | 74 | 72 | 76 |
| Haemonetics Corporation | 75 | 65 | 77 | 80 | 62 | 60 | 70 |
| Macopharma | 66 | 76 | 51 | 74 | 76 | 71 | 69 |
| Sartorius AG | 56 | 65 | 70 | 63 | 54 | 58 | 61 |
| Baxter International Inc. | 51 | 53 | 52 | 46 | 46 | 59 | 51 |
| Octapharma AG | 59 | 56 | 58 | 41 | 54 | 51 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius Kabi
- Terumo Corporation
- Grifols
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius Kabi | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Terumo Corporation | ◐ | ✓ | ✓ | − | ✓ | ◐ |
| Grifols | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Haemonetics Corporation | ◐ | ◐ | ✓ | ✓ | − | ◐ |
| Macopharma | ✓ | ✓ | − | ◐ | ◐ | ◐ |
| Sartorius AG | ◐ | − | − | ◐ | ◐ | − |
| Baxter International Inc. | − | − | − | − | − | ◐ |
| Octapharma AG | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius Kabi88
2Terumo Corporation80
3Grifols76
4Haemonetics Corporation70
5Macopharma69
6Sartorius AG61
7Octapharma AG53
8Baxter International Inc.51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fresenius KabiTerumo Corporation
Challenger3
Strong scale, closing on the leaders.
GrifolsHaemonetics CorporationMacopharma
Contender1
Focused players with pockets of strength.
Sartorius AG
Niche2
Specialists in a single segment or region.
Baxter International Inc.Octapharma AG
Go-to-market strategy
Land Donation Type in North America, then scale across Blood Donation Market — a $104M beachhead inside a $1.55B market.
Beachhead (SOM)$104Mobtainable near-term
Serviceable (SAM)$560Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Whole Blood Donation
Best fit — highest urgency & budget in Donation Type.
Economic buyer77 fit
Platelet Donation (Apheresis)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Plasma Donation (Plasmapheresis)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Donation Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Donor Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Donation Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Donation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified20%
Evaluation14%
Closed-won6%
$9.4KCAC
$50KLTV
5.3:1LTV : CAC
< 5 moCAC payback
Investment thesis
Blood Donation Market is a durable-growth opportunity — $5.67B by 2033, compounding at 8.1%.
TAM · 2025$3.04Btoday
TAM · 2033$5.67Bforecast
CAGR8.1%2027–2033
Cumulative$38.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.67BTotal addressable market
SAM$2.33BServiceable available market
SOM$500MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.1% CAGR
Demand compounds through 2033, outpacing GDP across Donation Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Donation Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.67BLarge & growingTAM by 2033 at 8.1% CAGR
$2.33BServiceable nowreachable with today’s model
$500MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.42BBear5.3% CAGR
$5.67BBase8.1% CAGR
$7.26BBull10.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Donor Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Donation Market — a $1.79B market by 2033. Plan: grow share from 10.4% to 17.2%.
Market size · 2033$1.79Btotal addressable
Market CAGR11.6%2027–2033
Target share17.2%from 10.4% today
Revenue ambition$308Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 17.2% | On track |
| Revenue | $187M | $308M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.0% | 42.8% | Ahead |
| Customer retention | 90.8% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Donation Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Donor Type capability
A defensible second engine — invest in Donor Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Donation Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Donor Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $40M capacity & capability investment
- Greenlight bolt-on M&A in Donor Type
- Authorise North America expansion plan
- Fund R&D program for Donation Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Sales deck · value proposition
Win the Blood Donation Market conversation — a $1.44B market you can size, segment and defend in minutes.
Market size · 2033$1.44Btotal opportunity
Growth8.2%CAGR to 2033
Addressable buyers1,788+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Donation Type
Goal Grow share in Donation Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 3 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Fresenius KabiTerumo CorporationGrifolsHaemonetics CorporationMacopharmaSartorius AGBaxter International Inc.Octapharma AG+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Donation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Donation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Donor Armchairs Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportBlood Electric Chair Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportBlood Factors Market
Market size, share, segmentation and regional forecast.
$416M market · 2025 base year
View reportBlood Flow Measurement Devices (Ultrasonic Doppler, Laser Doppler and Electromagnetic Blood Flowmeters) Market
Market size, share, segmentation and regional forecast.
$814M market · 2025 base year
View reportBlood Flow Restriction Bands Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportBlood Gas Analyzer with Touchscreen Market
Market size, share, segmentation and regional forecast.
$698M market · 2025 base year
View reportBlood Gas Analyzer/Blood Gas and Electrolyte Analyzer Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBlood Gas Electrolyte Analyzer Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportBlood Glucometer Market
Market size, share, segmentation and regional forecast.
$967M market · 2025 base year
View reportBlood Glucose (SMBG) (Test Strips, Lancet, Meter) Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportBlood Glucose Devices Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportBlood Glucose Meter Accessorie Market
Market size, share, segmentation and regional forecast.
$842M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.